ADVM

Adverum Biotechnologies, Inc.

1.96 USD
-0.01 (-0.51%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Adverum Biotechnologies, Inc. stock is up 127.91% since 30 days ago. The next earnings date is Mar 28, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 62.5% of the previous 7 February’s closed higher than January. 100% of analysts rate it a buy.

About Adverum Biotechnologies, Inc.

Adverum Biotechnologies, Inc. develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate. The company was incorporated in 2006 and is headquartered in Redwood City, California.